Freedom of Information request on the correspondaence with Biocomposites regarding the use of Stimulan (FOI 22/622)
Published 27 March 2023
FOI 22/622
11th May 2022
Dear
Thank you for your information request, 19 April 2022, where you asked us to “provide all correspondence with Biocomposites (https://www.biocomposites.com/ (and any of their affiliate companies) in respect of any material and/or promotional activities relating to the use of Stimulan as an antibiotic carrier”.
Unfortunately, the information is exempt from release under section:
Section 41 – Information provided in confidence: information provided to us in confidence, with the expectation that it will not be released, is exempt from disclosure under the FOI Act. Information will be covered by Section 41 if: it was obtained by the authority from any other person; its disclosure would constitute a breach of confidence; a person or organisation could bring a court action for that breach of confidence; and that court action would be likely to succeed.
If you have a query about the information provided, please reply to this email.
If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review would be carried out by a senior member of the Agency who was not involved with the original decision.
After that, if you remain dissatisfied, you may write to the Information Commissioner at;
The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
They will make a decision on whether or not we have interpreted the FOIA correctly in handling your request.
Yours sincerely
MHRA Customer Experience Centre